Key clinical point: A pooled analysis has confirmed the long-term survival benefit of using nivolumab versus docetaxel in patients with previously treated advanced non–small cell lung cancer.
Major finding: Across the four trials, the 4-year overall survival with nivolumab was 14%, including 11% for patients with under 1% programmed death–ligand 1 expression, and 19% for patients with a minimum of 1% programmed death–ligand 1 expression.
Study details: A combined analysis of four studies evaluating nivolumab in 664 patients with previously treated non–small cell lung cancer.
Disclosures: The study was funded by Bristol-Myers Squibb. The authors reported financial affiliations with AstraZeneca, Boehringer Ingelheim, Cellular Biomedicine Group, FLX Bio, Genentech, Novartis, Regeneron, and several others.
Antonia SJ et al. Lancet Oncol. 2019 Aug 14. doi: 10.1016/S1470-2045(19)30407-3.